Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02712398 · ClinicalTrials.gov registry record · NA

A Prospective Trial of a Bio-absorbable Mesh in Challenging Laparoscopic Ventral or Incisional Hernia Repair

A NA study, sponsored by C. R. Bard.

Completed
Registry status
NA
Development phase
120
Enrollment target

NCT02712398: Completed NA study, sponsored by C. R. Bard.

NCT02712398 is a NA study that has completed, run by C. R. Bard. The registered enrollment target is 120 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02712398, a NA study, has completed, sponsored by C. R. Bard.

COMPLETED
Registry status
NA
Development phase
120 participants
Enrollment target

Study Summary

The objective of this study is to collect additional data on safety, performance and effectiveness of Phasix™ ST in subjects receiving laparoscopic ventral or incisional hernia repair at high risk for surgical site occurrence (SSO).

Primary Outcome

Proportion of subjects with Surgical Site Occurrences(SSO), which are defined as hematoma, seroma, surgical site infection, wound dehiscence, skin necrosis and fistula requiring intervention. Occurrences at the surgical site will be assessed by physical examination at each study visit through 45 days.

Interventions

  • DEVICE Phasix™ ST

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2016-04
Est. Completion 2019-11-15
Phase NA
C. R. Bard

75 total trials

What the finished NCT02712398 record still lists

NCT02712398 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 1 intervention - of which Phasix™ ST is the first listed.

NCT02712398 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02712398 about?

NCT02712398 is a clinical study titled "A Prospective Trial of a Bio-absorbable Mesh in Challenging Laparoscopic Ventral or Incisional Hernia Repair". The objective of this study is to collect additional data on safety, performance and effectiveness of Phasix™ ST in subjects receiving laparoscopic ventral or incisional hernia repair at high risk for surgical site occurrence (SSO).

What is the current status of trial NCT02712398?

This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2016-04. Estimated completion is 2019-11-15.

What interventions are being tested in trial NCT02712398?

The interventions under investigation include: Phasix™ ST (DEVICE).

Who is sponsoring clinical trial NCT02712398?

This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02712398's enrollment target sits among peer trials

120 762nd of 2000 higher than 1,198 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02712398, the US trial registry maintained by the National Library of Medicine. NCT02712398 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.